ContraFect Corporation (CFRX) Stock Analysis
DELISTED 2023
What happened to ContraFect Corporation (CFRX) stock?
ContraFect Corporation (CFRX) no longer trades on public markets. It was delisted in November 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ContraFect Corporation (CFRX) trades at $0.05. ContraFect Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases. Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for CFRX: CFRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CFRX against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
CFRX: 2/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →ContraFect Corporation (CFRX) Healthcare & Pipeline Overview
ContraFect Corporation is a clinical-stage biotechnology firm specializing in therapeutic proteins and antibodies targeting life-threatening, drug-resistant infections. Their lead candidate, Exebacase, is in Phase III trials for Staphylococcus aureus bacteremia, positioning them in a critical area of unmet medical need within the biotechnology sector.
What Is the Investment Thesis for CFRX?
ContraFect Corporation presents a focused investment opportunity within the biotechnology sector, specifically targeting drug-resistant infectious diseases. The primary value driver is Exebacase, currently in Phase III trials for Staphylococcus aureus bacteremia. Successful trial outcomes and subsequent FDA approval could lead to significant revenue generation, addressing a critical unmet need in treating severe infections. The company's pipeline, including CF-296 and CF-370, offers additional potential revenue streams, targeting a broader range of bacterial infections. Growth catalysts include the progression of Exebacase through clinical trials, potential partnerships for commercialization, and expansion of the pipeline through the Rockefeller University agreement. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from existing and emerging therapies. With a beta of 0.29, the stock demonstrates lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
CFRX Key Highlights
Exebacase, ContraFect's lead program, is in Phase III clinical trials for the treatment of Staphylococcus aureus bacteremia, representing a significant milestone in its development.
- ContraFect is developing CF-296, an engineered lysin, targeting invasive infections caused by Staphylococcus aureus, including biofilm-related infections, expanding its therapeutic focus.
- CF-370, an investigational anti-bacterial therapeutic candidate, is in Phase 1 clinical trials to treat Pseudomonas aeruginosa infections, addressing a different spectrum of bacterial threats.
- The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens, enhancing its research capabilities.
- ContraFect initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients, showcasing its commitment to addressing emerging infectious disease challenges.
Who Are CFRX's Competitors?
CFRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
| EXEL Exelixis, Inc. | $53.69 | -1.29% | $13.5B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CFRX's Key Strengths?
Novel lysin technology targeting drug-resistant bacteria.
- Lead product candidate, Exebacase, in Phase III clinical trials.
- Pipeline of product candidates addressing a range of bacterial infections.
- License agreement with The Rockefeller University for novel lysin discovery.
What Are CFRX's Weaknesses?
Clinical-stage company with no currently marketed products.
- Reliance on successful clinical trial outcomes and regulatory approvals.
- Limited financial resources compared to larger pharmaceutical companies.
- High risk of clinical trial failure and regulatory setbacks.
What Could Drive CFRX Stock Higher?
Announcement of Phase III clinical trial results for Exebacase in Staphylococcus aureus bacteremia.
- Potential FDA approval of Exebacase, contingent on positive trial results.
- Progression of CF-296 and CF-370 through clinical trials.
- Expansion of pipeline through the Rockefeller University agreement.
- Potential partnerships and collaborations with larger pharmaceutical companies.
What Are the Key Risks for CFRX?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure of Exebacase to achieve positive results in Phase III clinical trials.
- Regulatory setbacks and delays in FDA approval process.
- Competition from established pharmaceutical companies and other biotechnology firms.
- Limited financial resources and reliance on future funding.
- Uncertainty surrounding the commercial success of Exebacase and other product candidates.
What Are the Growth Opportunities for CFRX?
- Exebacase Commercialization: Successful completion of Phase III trials and subsequent FDA approval for Exebacase could unlock a significant market opportunity in treating Staphylococcus aureus bacteremia. The market for treating severe bacterial infections is estimated to be in the billions of dollars annually, with a growing need for novel therapies to combat drug resistance. Timeline: Potential FDA approval within the next 2-3 years, contingent on positive trial results.
- CF-296 Development: Advancing CF-296, an engineered lysin, through clinical trials could expand ContraFect's product portfolio and address invasive infections caused by Staphylococcus aureus, including biofilm-related infections. The market for treating biofilm-related infections is substantial, given the challenges associated with eradicating these infections. Timeline: Clinical trials expected to progress over the next 3-5 years.
- CF-370 Advancement: Progressing CF-370, an investigational anti-bacterial therapeutic candidate, through clinical trials could provide a solution for Pseudomonas aeruginosa infections, such as ventilator-associated pneumonia. The market for treating Pseudomonas aeruginosa infections is significant, particularly in hospital settings. Timeline: Clinical trials expected to progress over the next 4-6 years.
- Partnerships and Collaborations: Establishing partnerships with larger pharmaceutical companies or research institutions could provide ContraFect with additional funding, expertise, and resources to accelerate the development and commercialization of its product candidates. Strategic alliances could also expand the company's reach and market access. Timeline: Ongoing efforts to establish partnerships.
- Expansion of Lysin Platform: Leveraging the license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens could broaden ContraFect's pipeline and address a wider range of bacterial infections. The market for treating gram-negative bacterial infections is substantial, given the increasing prevalence of drug resistance. Timeline: Ongoing research and development efforts.
What Threats Does CFRX Face?
- Competition from established pharmaceutical companies and other biotechnology firms.
- Risk of clinical trial failure and regulatory setbacks.
- Changes in regulatory landscape and reimbursement policies.
- Emergence of new drug-resistant bacteria.
What Are CFRX's Competitive Advantages?
- Proprietary Lysin Technology: ContraFect's focus on lysins provides a differentiated approach to combating drug-resistant infections, potentially offering a competitive advantage over traditional antibiotics.
- Strong Intellectual Property: The company has patents and intellectual property rights protecting its product candidates and technology, providing a barrier to entry for competitors.
- Clinical-Stage Pipeline: ContraFect's pipeline of product candidates in various stages of clinical development represents a valuable asset and potential future revenue streams.
- Strategic Collaborations: The company's collaborations with research institutions and pharmaceutical companies provide access to expertise, resources, and market access.
What Does CFRX Do?
ContraFect Corporation, established in 2008 and headquartered in Yonkers, New York, is a clinical-stage biotechnology company dedicated to discovering and developing therapeutic protein and antibody products. The company focuses on addressing life-threatening and drug-resistant infectious diseases, a growing concern in the healthcare industry. ContraFect's lead program is Exebacase, a lysin currently in Phase III clinical trials, targeting Staphylococcus aureus bacteremia, a severe bloodstream infection. Beyond Exebacase, ContraFect is developing CF-296, an engineered lysin designed to treat invasive infections caused by Staphylococcus aureus, including biofilm-related infections associated with prosthetic joints, indwelling devices, and osteomyelitis. The company's pipeline also includes CF-370, an investigational anti-bacterial therapeutic candidate in Phase 1 clinical trials, aimed at treating Pseudomonas aeruginosa infections, such as ventilator-associated pneumonia, bloodstream infections, complicated urinary tract infections, and surgical site infections. ContraFect also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) in COVID-19 patients. Furthermore, the company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens, expanding its research and development capabilities. ContraFect's focus on lysins, naturally occurring enzymes that kill bacteria, represents a novel approach to combating drug-resistant infections.
What Products and Services Does CFRX Offer?
- Discovers and develops therapeutic protein and antibody products.
- Focuses on treating life-threatening and drug-resistant infectious diseases.
- Develops lysins, which are naturally occurring enzymes that kill bacteria.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Seeks regulatory approvals from the FDA to commercialize its products.
- Collaborates with research institutions and pharmaceutical companies to advance its pipeline.
How Does CFRX Make Money?
- Develops and patents novel therapeutic protein and antibody products.
- Conducts clinical trials to demonstrate the safety and efficacy of its products.
- Seeks regulatory approval from the FDA to commercialize its products.
- May partner with larger pharmaceutical companies for commercialization and distribution.
What Industry Does CFRX Operate In?
ContraFect Corporation operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The increasing prevalence of drug-resistant infections is driving demand for novel therapeutic approaches, positioning companies like ContraFect at the forefront of addressing this critical need. The competitive landscape includes established pharmaceutical companies and other biotechnology firms focused on developing anti-infective agents. ContraFect's focus on lysins offers a differentiated approach compared to traditional antibiotics, potentially providing a competitive advantage in the market.
Who Are CFRX's Key Customers?
- Hospitals and healthcare providers treating patients with severe bacterial infections.
- Patients suffering from life-threatening and drug-resistant infectious diseases.
- Pharmaceutical companies seeking to expand their anti-infective product portfolios.
- Government agencies and research institutions focused on combating infectious diseases.
Company Profile
ContraFect Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Yonkers, US. The company is led by CEO Michael Messinger CPA. CFRX has traded publicly since 2014.
Financial Health
ContraFect Corporation's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
CFRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's upcoming clinical trials, indicating potential breakthroughs.
- Social sentiment has shifted positively as discussions around their innovative therapies gain traction in biotech communities.
- Analysts are increasingly recognizing the potential of ContraFect's pipeline, leading to heightened interest among retail investors.
- Recent collaborations with research institutions have sparked optimism about the company's future growth and market positioning.
Bear Case
- Concerns linger around the pace of clinical trial results, with some investors expressing skepticism about timelines.
- Community sentiment has shown volatility, with recent discussions reflecting apprehension about regulatory hurdles.
- Market perception has been clouded by broader economic factors impacting biotech funding, causing some investors to hesitate.
- Increased competition in the biotech space has raised doubts about ContraFect's ability to maintain its edge in innovation.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
CFRX Latest News
No recent news available for CFRX.
Leadership: Michael Messinger CPA
CEO
Michael Messinger is the Chief Executive Officer of ContraFect Corporation. He is a Certified Public Accountant (CPA) and brings extensive financial and operational experience to the company. His background includes leadership roles in various healthcare and biotechnology companies, where he has been responsible for financial management, strategic planning, and business development. His expertise in financial management is crucial for guiding ContraFect through its clinical development programs and potential commercialization efforts.
Track Record: Under Michael Messinger's leadership, ContraFect has focused on advancing its lead program, Exebacase, through Phase III clinical trials. He has also overseen the expansion of the company's pipeline through internal research and external collaborations. His strategic decisions have been instrumental in securing funding and partnerships to support the company's growth and development. He manages a team of 23 employees.
What Investors Ask About ContraFect Corporation (CFRX) — Healthcare
What happened to ContraFect Corporation (CFRX) stock?
ContraFect Corporation (CFRX) no longer trades on public markets. It was delisted in November 2023. The figures below are historical and are not a current quote.
Can I still buy CFRX shares?
No. CFRX stopped trading on public markets in November 2023, so the shares are not available through a broker. Anything you see quoted for CFRX elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before CFRX stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to ContraFect Corporation. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does ContraFect Corporation do?
ContraFect Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases. The company's lead program, Exebacase, is in Phase III clinical trials for the treatment of Staphylococcus aureus bacteremia.
What do analysts say about CFRX stock?
Analyst coverage of ContraFect Corporation (CFRX) is limited, reflecting its clinical-stage status and inherent risks associated with biotechnology companies. Key valuation metrics are heavily dependent on the success of Exebacase in Phase III trials and its potential for FDA approval. Growth considerations revolve around the advancement of its pipeline and potential partnerships.
What are the main risks for CFRX?
ContraFect Corporation faces several key risks inherent to its business model and the biotechnology industry. The most significant risk is the potential failure of Exebacase to achieve positive results in Phase III clinical trials, which would significantly impact the company's value. Regulatory setbacks and delays in the FDA approval process also pose a threat.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Investment in biotechnology companies carries significant risk.